List view / Grid view
Following Zymeworks’ presentation at AACR 2024, in this Q&A, Dr Nina Weisser explains how the next generation trispecific T cell engager platform with integrated CD28 costimulation is engineered to tackle solid tumours.
In this Q&A, Erik Wiklund, CEO of Circio, explains the key findings of their circVec circular RNA platform technology, why they chose AAV-based gene therapy for AATD as the lead programme, and their plans for the future to enhance the potency and reduce the cost of current gold-standard gene therapy.
In assays and patient-derived organoids, the small molecule inhibitor CBR-5884 successfully treated epithelial ovarian cancer.
Through in vitro and in vivo models, researchers find a mechanism by which bacteria-generated fatty acids regulate immune responses.
In this Q&A, we speak to Dr Emma Murphy, Head of Biology at the Alzheimer’s Research UK Oxford Drug Discovery Institute. Among her many insights, she discusses how the challenges in developing reproducible assays can be addressed, as well as strategies used to translate promising findings into clinically relevant tools…
In mouse models, the differences between oocytes collected by natural or stimulated approaches were investigated.
Researchers have presented new findings that offer potential pathways to arrest critical steps toward the accumulation of mutant tau.
The compound 11c demonstrates an excellent safety profile and is an exciting advancement in liver disease management.
Stem-cell based blastocyst models have enabled scientists to redefine the molecular signature and timing of the onset of gastrulation.
Scientists have reported a promising technique, based on somatic cell nuclear transfer, to treat infertility.
Researchers find that an overgrowth of nerve cells in the bladder could cause rUTIs, which may offer new approaches to manage symptoms.
28 February 2024 | By Eurofins DiscoverX
Watch this webinar to learn about recently published research toward the advancement of non-opioid analgesics targeting the Nav1.8 ion channel, a validated pain target primarily found in peripheral nociceptors.
Researchers found that the D48 antibody neutralised HSV-1 virus infection, which could lead to broad-spectrum drug and vaccine development.
Researchers have created dual-targeted CARs, which performed better than single-targeted CARs in both in vivo and in vitro experiments.
Explore an MEA workflow used to validate the ALS-relevant phenotype of precision reprogrammed iPSC-derived neuronal disease models of ALS from bit.bio
